## Management of Stevens-Johnson Syndrome (SJS) ### Diagnosis and Immediate Step **Key Point:** The clinical presentation—target lesions, mucosal involvement, fever, and temporal relationship to drug exposure—is diagnostic of SJS. The first and most critical intervention is **immediate discontinuation of the offending agent** (trimethoprim-sulfamethoxazole in this case). ### Pathophysiology Context SJS is a severe cutaneous adverse reaction (SCAR) mediated by cytotoxic T cells (CD8+) targeting keratinocytes. Continued exposure to the culprit drug perpetuates the immune cascade and worsens outcome. ### First-Line Management Hierarchy | Intervention | Role | Evidence | |---|---|---| | **Drug withdrawal** | Essential, non-negotiable | Halts disease progression; mortality increases if drug continued | | **Supportive care** | Cornerstone of management | Fluid/electrolyte balance, infection prevention, eye care, nutritional support | | **Systemic corticosteroids** | Controversial, not first-line | Meta-analyses show no mortality benefit; may increase infection risk | | **IVIG** | Consider in severe/refractory cases | Limited evidence; reserved for TEN or SJS with poor prognosis | | **Cyclosporine** | Emerging alternative | Some case series suggest benefit; not standard first-line | ### Clinical Pearl **High-Yield:** In SJS/TEN, **supportive care + drug withdrawal = standard of care**. Systemic corticosteroids are NOT first-line and may be harmful. IVIG and cyclosporine are adjunctive agents for severe, rapidly progressive cases or TEN, not initial therapy for SJS. ### Why Supportive Care Is Correct 1. Removes the inciting stimulus (drug discontinuation) 2. Prevents complications (infection, dehydration, eye damage) 3. Allows natural resolution in most SJS cases 4. No iatrogenic harm from immunosuppression [cite:Robbins 10e Ch 25] --- ## Why Each Distractor Is Wrong **Systemic corticosteroids (Option 0):** - Early high-dose corticosteroids are **not recommended** as first-line therapy for SJS. Multiple meta-analyses (including a Cochrane review) have failed to demonstrate mortality benefit and suggest increased infection risk. - Corticosteroids may be considered in severe TEN (>30% BSA) as adjunctive therapy only, after drug withdrawal and supportive care are established. **IVIG (Option 1):** - IVIG is reserved for **severe, rapidly progressive SJS or TEN** (especially >30% BSA involvement or high-risk features). - In this case, the patient has <10% BSA involvement (SJS, not TEN), so IVIG is not first-line. - IVIG is an adjunctive agent, not the primary intervention. **Cyclosporine (Option 2):** - Cyclosporine is an emerging alternative for severe SJS/TEN based on small case series, but it is **not standard first-line therapy**. - It is considered only in severe, refractory cases or when IVIG is unavailable or contraindicated. - Requires careful monitoring for nephrotoxicity and drug interactions.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.